Future investigations have to show to what extent MCT1-driven lactate operates as an alternative event to macropinocytosis and/or how these two events act synergistically, e.g., in the context of tumor–stroma interactions with CAFs. The gene discussed is SLC16A1; the disease is neoplasm.